Cancer
Malignant Uterine Corpus Neoplasm
CI-CAN-00008020Explore in graph →
Top-level411 active trials4 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00008020Explore in graph →
Clinical trials
1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Leon BerardOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT05483023 | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 14, 2025 | clinicaltrials |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer(LiDer) | withdrawn | Phase 1 / Phase 2 | 0 | Vall d'Hebron Institute of OncologyOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 6 | Apr 30, 2024 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT02127151 | A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer(PANDA) | withdrawn | Phase 2 | 0 | University College, LondonOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04197219 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Nov 5, 2020 | clinicaltrials |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT00003821 | Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer | withdrawn | Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02042495 | Endometrial Cancer Biomarker Changes Following Exposure to Metformin | withdrawn | Phase 2 | 0 | Jewish General HospitalOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 0 | Sep 10, 2014 | clinicaltrials |
| NCT01550380 | BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers(BKM120) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Jul 29, 2014 | clinicaltrials |
| NCT01290406 | BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 21, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 23, 2026source: clinicaltrials